Introduction
In recent years, Mounjaro (generic name: tirzepatide), used as a once-weekly subcutaneous injection, has been drawing attention as a new option for obesity treatment. This drug is a dual agonist that stimulates both “GIP” and “GLP‑1,” and its key feature is that it promotes weight loss through several pathways, including appetite, metabolism and blood sugar. In this article, based on data from clinical trials and real-world practice, we explain in detail and in plain terms how soon Mounjaro starts to take effect after you begin, and which side effects are more likely to occur.
The short answerIf you’re busy, just read this part
- Appetite suppression with Mounjaro starts within 1–2 weeks, and visible weight loss appears at 4–8 weeks
- Side effects are mainly digestive symptoms; serious ones such as gallstones or pancreatitis are rare but require caution
- The risk of weight regain after stopping is high, so diet, exercise, psychological support and a gradual tapering plan are essential
How long until it starts working: a stage-by-stage guide
1.1 1–2 weeks: early changes
Many people notice a sense that their appetite is being curbed within about 1–2 weeks. This is because Mounjaro acts early on the hormones that control appetite, and it is an important change as the first step toward weight loss .
1.2 4–8 weeks: when weight loss starts to show
Clinical studies often report that “meaningful weight loss” is seen from week 4 onward, particularly around week 8. In general, a 6–8% reduction in body weight is considered possible in the early stage, and depending on the dose, a 5% reduction may be reached at 12–16 weeks.
1.3 3–6 months: the effect becomes fully apparent, with striking changes
Several cases have been reported of 10–20% total body weight loss within 3–6 months of starting treatment. This period is also important as the point at which the effect becomes most evident .
For example, with 72 weeks of continuous treatment, weight loss of about 15% at 5 mg, about 19.5% at 10 mg, and up to about 20.9% at 15 mg was observed .
1.4 Long term (1 year or more): maintaining weight or losing more
As long-term data, in the SURMOUNT-1 trial, a maximum reduction of 23.1% was reached at an average of 22 months, and an average reduction of 19.4% was ultimately maintained. Many (most) participants maintained their weight without regaining 5% or more of their original weight .
Side effect trends and how they change over time
2.1 Digestive symptoms common early on
The most common side effects of Mounjaro are digestive symptoms such as nausea, diarrhea, constipation, vomiting and indigestion.
These are especially noticeable right after starting or right after a dose increase, and tend to ease as the body gradually adjusts .
2.2 Other reactions
Redness or pain at the injection site, fatigue, reduced appetite and abdominal pain have also been reported, but most are mild and mainly temporary .
2.3 Reports of rare serious complications
Although very rare, risks such as pancreatitis, gallstones and thyroid tumors (with many contraindications set by Japan’s Ministry of Health, Labour and Welfare) have been pointed out. However, a clear causal relationship in humans has not been established, and careful monitoring is needed .
There have also been reported cases of vision problems (such as loss of visual field) and problems related to the thyroid, heart and thyroid function, but a causal relationship has not been established .
Summary table: effects and care points by period
| Period | Main effects and reactions | Care points |
|---|---|---|
| 1–2 weeks | Appetite suppression begins | Reduce strain on the stomach by staying hydrated and adjusting portion sizes |
| 4–8 weeks | 6–8% weight loss starts to be seen | Managing mild side effects (nausea, diarrhea, etc.) and staying motivated to continue |
| 3–6 months | Weight loss of 10–20% may be seen | Establishing exercise and eating habits; ongoing care to reduce side effects |
| 1 year or more | Steady maintenance, or further weight loss, is possible | Regular checkups, dose adjustment, reviewing lifestyle and maintaining motivation |
Not sure if it suits you? Start with a consultation.
A doctor decides whether you can use it and which dose is appropriate, based on your consultation and questionnaire.
No consultation fee (first & follow-up visits)Online consultation available
Practical tips for successful treatment
Work closely with your doctor and follow the starting dose and schedule
Regular evaluations allow the balance between effects and side effects to be adjusted.
Address digestive side effects while they are still mild
Try strategies such as drinking fluids frequently, eating small frequent meals, choosing gentle foods, and consulting about medication.
Improve lifestyle habits as your weight changes
Support weight loss with exercise, a protein-focused diet, and good sleep and stress management.
Take a long-term view
Committing to a steady approach over a year or more is the shortest path to lasting health.
Synergy with lifestyle habits
Mounjaro has a strong weight-loss effect, but rather than relying on the medication alone, combining it with lifestyle habits is the key to success.
Diet
Eating habits centered on high-protein, low-GI foods help maximize the effect of the medication and prevent weight regain.
Exercise
150 minutes of aerobic exercise per week plus strength training twice a week are effective for maintaining basal metabolism and burning fat.
Sleep
Lack of sleep increases the appetite hormone (ghrelin), so getting enough sleep, 7–9 hours, is necessary.
Stress management
Stress can easily lead to overeating and overdrinking; making time for meditation or hobbies helps reduce this risk.
Key point
By using the effect of the medication as a “starting point” to build healthy lifestyle habits, long-term success becomes possible.

A closer look at the effects seen in clinical trials
6.1 Results of the SURMOUNT-1 trial
The SURMOUNT-1 trial, conducted mainly in the United States, reported results of giving Mounjaro for 72 weeks to 2,539 adults with obesity or overweight.
5 mg group
Average weight loss of about 15%
10 mg group
Average weight loss of about 19.5%
15 mg group
Average weight loss of up to 20.9%
Key point
Notably, a higher rate of weight loss was observed than with conventional GLP-1 drugs. As a result, Mounjaro is attracting attention as a drug showing “among the largest weight-loss effects achievable with drug therapy.”
6.2 Long-term maintenance
In a later follow-up study, the group that continued for 3 years maintained an average weight loss of 19.4%, showing that when combined with lifestyle improvements, “long-term management is possible while limiting weight regain.”
Differences in effect by patient background
7.1 Differences by sex and age
- Men have more muscle mass and a higher basal metabolism, so they tend to have a slightly lower rate of weight loss but also less regain.
- Women, influenced by hormonal balance, often feel the appetite-suppressing effect strongly, and weight loss may be pronounced in the short term.
- Older adults lose muscle mass more easily, and the risk of sarcopenia (age-related muscle loss) rises along with weight loss, so managing nutrition and exercise is especially important.
7.2 Patients with other conditions
In patients who also have diabetes, blood sugar may improve as well, but care is needed regarding hypoglycemia and digestive symptoms. In patients at risk of cardiovascular disease, weight loss and lower blood pressure are expected to improve the long-term outlook.
Managing the risk of side effects
8.1 Ways to reduce digestive symptoms
Nausea, diarrhea and similar symptoms may be reduced by starting at a low dose and increasing gradually. It has also been reported that avoiding fatty meals and drinking fluids frequently can help ease symptoms.
8.2 Risk of gallstones and pancreatitis
As a risk common to GLP-1 drugs in general, the incidence of gallstones and pancreatitis is known to be slightly higher. If symptoms such as severe abdominal pain or jaundice appear, you need to see a doctor immediately.
8.3 Effects on the thyroid
Rat studies have pointed to an increased risk of thyroid tumors, so people with a history of thyroid disease need to consider its use carefully. Although a clear causal relationship in humans has not yet been established, regular checks by a doctor are recommended.
Not sure if it suits you? Start with a consultation.
A doctor decides whether you can use it and which dose is appropriate, based on your consultation and questionnaire.
No consultation fee (first & follow-up visits)Online consultation available
Preventing weight regain and long-term strategy
9.1 Challenges after stopping
As many studies have shown, when Mounjaro is stopped, appetite returns and weight tends to rebound within a few months. In particular, weight often returns within a year, so a strategy is essential for long-term weight maintenance.
9.2 Specific measures
Diet management
Maintain fullness with high-protein, low-GI meals
Exercise habits
Keep up strength training so your basal metabolism doesn’t drop
Psychological support
Use counseling or group support to ease anxiety about weight regain
Gradual tapering plan
Instead of stopping the medication suddenly, reduce it gradually under a doctor’s guidance
Future research and outlook
GLP-1 drugs, including Mounjaro, are expected to play a major role not only in obesity but also in the prevention and treatment of diabetes and cardiovascular disease. Oral versions (pills) are also being developed, and in the near future it will likely become possible to choose treatments that are easier to continue.
In addition, new drugs such as retatrutide, which also have actions beyond GLP-1, are being developed, and treatment options that are even more potent with fewer side effects are expected to emerge in the future.
About self-pay treatment and off-label use
FAQ
QWhen does Mounjaro start to take effect?
Appetite suppression with Mounjaro starts within 1–2 weeks, and visible weight loss appears at 4–8 weeks.
QWhat are the common side effects of Mounjaro?
The most common side effects of Mounjaro are digestive symptoms such as nausea, diarrhea, constipation, vomiting and indigestion.
QWill I regain weight if I stop Mounjaro?
As many studies have shown, when Mounjaro is stopped, appetite returns and weight tends to rebound within a few months.
QIs there a risk of gallstones or pancreatitis?
As a risk common to GLP-1 drugs in general, the incidence of gallstones and pancreatitis is known to be slightly higher.
If symptoms such as severe abdominal pain or jaundice appear, you need to see a doctor immediately.
QDo I need to improve my lifestyle habits rather than relying on the medication alone?
Mounjaro has a strong weight-loss effect, but rather than relying on the medication alone, combining it with lifestyle habits is the key to success.
Not sure? Talk to us
No consultation fee (first & follow-up visits)Online consultation available
Toll-free 0120-241-929 (toll-free in Japan, 9:00–18:00 JST, Japanese only)
Summary
- Appetite suppression with Mounjaro starts within 1–2 weeks, and visible weight loss appears at 4–8 weeks.
- Weight loss of 10–20% at 3–6 months is achievable, and with use for a year or more it can be maintained steadily.
- Side effects are mainly digestive symptoms; serious ones such as gallstones or pancreatitis are rare but require caution.
- The risk of weight regain after stopping is high, so diet, exercise, psychological support and a gradual tapering plan are essential.
- Oral medications and drugs with new mechanisms of action are expected to appear, further expanding the options.
Mounjaro is “an obesity medication that combines fast onset with lasting effect,” but to make the most of it, you need to combine it with lifestyle habits under a doctor’s guidance and plan a long-term strategy.
References (evidence)
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022.
- Aronne LJ, et al. Continued Treatment with Tirzepatide for Maintenance. PMC. 2023.
- Ghusn W, et al. Weight loss outcomes, tolerability, side effects, and risks. ScienceDirect. 2024.
- InstantUC: How Long Does Tirzepatide Take to Work?
- DrOracle.ai: How long does it take for Mounjaro to take effect? 2025.
- NEJM: Tirzepatide Compared with Semaglutide for Obesity. May 2025.
- Wikipedia: Tirzepatide summary. Nature Medicine: GLP-1 receptor agonist safety profile.
- The Guardian: Long-term SURMOUNT-1 three-year results.
- JAMA Ophthalmology reviews (vision risks).
- Business Insider: rare thyroid-related complications.
Who to contact if side effects occur | When to see a doctor
If any of the following symptoms occur, please contact us rather than deciding on your own to wait and see. GIP/GLP-1 receptor agonists, including Mounjaro, are known to cause side effects, mainly digestive symptoms. Most are mild, but serious ones occur in rare cases.
| Symptom | Possible cause | What to do |
|---|---|---|
| Persistent nausea or vomiting | Digestive symptoms; the most common side effect | Please contact us if you remain unable to keep fluids down |
| Severe abdominal pain (pain radiating to the back) | Possible acute pancreatitis | Stop the medication immediately and see a doctor |
| Cold sweats, palpitations, intense hunger, or feeling confused or drowsy | Hypoglycemia | Take sugar right away and contact us |
| Skin rash, difficulty breathing, or swelling of the face or throat | Allergic reaction | See a doctor immediately |
If your symptoms are severe outside our hours, please go to your nearest emergency medical facility.
Each clinic’s direct phone number is listed on the clinic information page.
References
The information about medications in this article is based on the following official sources. For details on dosage and administration and on side effects, always check the latest electronic package insert.
Pharmaceuticals and Medical Devices Agency (PMDA): “Mounjaro Subcutaneous Injection Ateos, electronic package insert”
PMDA: “Drug Guide for Patients: Mounjaro Subcutaneous Injection Ateos” (PDF)
Ministry of Health, Labour and Welfare: “Prevention of lifestyle-related diseases”
When Mounjaro is used for purposes other than obesity disease, it is self-pay treatment and is not covered by Japan’s public health insurance. Effects and side effects vary from person to person.



